These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8424909)

  • 41. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):273-5. PubMed ID: 1396075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
    Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
    Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
    Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
    Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
    Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ
    Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
    Fox SM; Einhorn LH; Cox E; Powell N; Abdy A
    J Clin Oncol; 1993 Dec; 11(12):2391-5. PubMed ID: 8246028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of ondansetron in paediatric patients: a review of three studies.
    Stevens RF
    Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL; Milne RJ
    Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
    Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
    Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
    Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
    Holdsworth MT; Raisch DW; Winter SS; Chavez CM
    Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.
    Herrstedt J; Summers Y; Daugaard G; Christensen TB; Holmskov K; Taylor PD; Fox GM; Molassiotis A
    Support Care Cancer; 2018 Jan; 26(1):139-145. PubMed ID: 28801850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M; Droz JP; Pouillart P; Paule B; Brion N; Bons J
    Cancer Chemother Pharmacol; 1989; 23(6):389-91. PubMed ID: 2523762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ondansetron as an effective drug in prophylaxis of chemotherapy--induced emesis in children.
    Kołecki P; Wachowiak J; Beshari SE
    Acta Haematol Pol; 1993; 24(2):115-22. PubMed ID: 8372610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
    Herrstedt J; Sigsgaard T; Handberg J; Schousboe BM; Hansen M; Dombernowsky P
    J Clin Oncol; 1997 Apr; 15(4):1690-6. PubMed ID: 9193370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.